Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma

10 Jul 2014

Abstract excerpt

PURPOSE: Approximately 50% of patients with diffuse large B-cell lymphoma (DLBCL) enter long-term remission after standard chemotherapy. Patients with DLBCL who do not respond to chemotherapy have few treatment options. There remains a critical need to identify effective and targeted therapeutics for DLBCL. EXPERIMENTAL DESIGN: Recent studies have highlighted the incidence of increased c-MYC protein in DLBCL and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Click Chemistry and Applications
Share to Lymphoma Diagnosis and Treatment
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25009295
DOI: 10.1158/1078-0432.ccr-13-3346

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell LymphomaPMID 25009295Read ↗

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemiaSemantic proximity Read ↗

Targeting BET Bromodomains for Cancer TreatmentSemantic proximity Read ↗

BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1Semantic proximity Read ↗

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical ApplicationsSemantic proximity Read ↗

Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancerSemantic proximity Read ↗

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-MycSemantic proximity Read ↗

Targeting MYC dependence in cancer by inhibiting BET bromodomainsSemantic proximity Read ↗

Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in miceSemantic proximity Read ↗

The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft modelsSemantic proximity Read ↗

Targeting BET bromodomain proteins in cancer: The example of lymphomasSemantic proximity Read ↗

Bromodomain inhibitor treatment leads to overexpression of multiple kinases in cancer cellsSemantic proximity Read ↗

Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of small molecule inhibitor JQ1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.